DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

	I/We verily believ I am/	t office address(es) and citi we are the original, first an sought on the invention ent	zenship(s) are as stated below my name(s). d sole/joint inventor(s) of the subject matter which is claimed itled:
	Timing Cura	tion of Administration of	Adenosine A1/A2 Agonist for Cardioprotection
	and the specification of w (check one)	was filed on and was amend was described	eto (Aventis Docket No. USAV2001/0092 US CNT) as U.S. Application Number ded on (if applicable). and claimed in PCT Int'l Application Number filed on samended under PCT Article 19 on (if any).
	including the claims as an I/We acknowledge the du	nended by any amendmeni	atent and Trademark Office all information known to me/us to
	application(s) for patent of least one other country of the application on which	r inventor's certificate, or 36 ther than the United States priority is claimed. I/We h	e 35, United States Code §119(a)-(d) or 365 (b) of any foreign 65(a) of any PCT international application which designated at of America, listed below and having a filing date before that of ave also identified below any foreign application for patent or of the application on which priority is claimed:
Foreign	0120124.3	United Kingdom	17/08/2001
Priority:	Number	Country	Day/Month/Year Filed
Prior Foreign	Number	Country	Day/Month/Year Filed
Appln(s):			
\boxtimes	I/We hereby claim the application(s) listed belo	benefit under Title 35, Un w:	ited States Code §119(e) of any United States Provisional
	60/288,936 Number	May 4, 2001 Filing Date	_
	application(s) or internati matter of each of the clai provided by the first par information which is mat	onal application designatin ns of this application is not agraph of Title 35, United erial to patentability as de	Inited States Code §120 or 365(c) of any United States g the United States listed below and, insofar as the subject disclosed in the prior United States application in the manner States Code §112, IWe acknowledge the duty to disclose fined in Title 37, Code of Federal Regulations §1.56 which application and the national or PCT international filing date of
	PCT/US02/14228 Application Serial No.	May 3, 2002 Filing Date	Pending Status (Patented, Pending)
and belief ar and the like	e believed to be true; and so made are punishable b	further that these statemen y fine or imprisonment, or t	owledge are true and that all statements made on information ts were made with the knowledge that willful false statements both, under Title 18, United States code §1001, and that such n or any patent issued thereon.
Inventors(s):	Additional names	and signatures are attache	d.
1. Full name: 2	Zhelong XU		2. Full name: James M. DOWNEY
Signature:			Signature:
			The state of the s
Country of Citi	zenship: China		Country of Citizenship: United States
Residence: Ch			Residence: Mobile, AL
	(City and State/City and Cou	ntry only)	(City and State/City and Country only)
P. O. Address:	114 Melville Loop #15		P. O. Address: 1220 Anchor Drive
	Chapel Hill, NC 27599		Mobile, AL 36693

3. Full name:	4. Full name:
Signature:	Signature:
Date:	
Country of Citizenship:	
	Residence:
Residence:(City and State/City and Country only)	Residence: (City and State/City and Country only)
P. O. Address:	
5. Full name:	6. Full name:
Signature:	Signature:
5. Full name:	Signature:
Signature: Date: Country of Citizenship:	Signature: Date: Country of Citizenship:
Signature:	Signature: Date: Country of Citizenship: Residence: (City and State/City and Country only)

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-3582
Telefax (908) 231-2626

Aventis Docket No. USAV2001/0092 US CNT